TB-500 Dosage Protocol

In short: TB-500 is a short fragment of thymosin beta-4 dosed in the low-milligram range weekly, supported by preclinical Tβ4 data — but the fragment itself has no completed human efficacy trials and vendors routinely mislabel it as the full protein.

TB-500 is a synthetic peptide corresponding to the amino acid sequence 17-23 (LKKTETQ) of thymosin beta-4 (Tβ4), the actin-sequestering protein that is among the most abundant peptides in mammalian cells [1]. The fragment was developed as a research tool because this short sequence was shown to retain a substantial portion of the cell-migration and wound-healing activity of the parent protein, while being far cheaper to manufacture [1,2]. Reported protocols in the research-chemical community describe a distinct loading-phase pattern: approximately 2 to 2.5 milligrams subcutaneously once or twice weekly for four to six weeks, followed by a lower-dose maintenance phase of roughly 2 to 2.5 milligrams every two to four weeks [3].

How TB-500 Works: Mechanism of Action

In short: the LKKTETQ sequence sits inside the actin-binding region of thymosin beta-4, and that's the basis for every claim about wound healing, angiogenesis, and cardiac repair — all of it preclinical.

Thymosin beta-4 is a 43-amino-acid intracellular peptide whose best-characterized function is the sequestration of monomeric (G-) actin via its actin-binding domain, which spans residues 17 to 23. TB-500 is the seven-amino-acid fragment corresponding to this core region, plus, in most commercial preparations, an acetylation or extended-sequence modification intended to improve solubility and stability [1,2]. Research groups have reported that the LKKTETQ motif retains much of the cell-migratory and angiogenic activity of the parent protein in cultured endothelial and keratinocyte systems [2].

Downstream mechanisms attributed to thymosin beta-4 and, by extension, to TB-500 include upregulation of laminin-5 in epidermal wound healing, activation of the Akt survival pathway in ischemic tissues, and recruitment of endothelial progenitor cells to injured vasculature [2,4]. In murine dermal wound models, topical and systemic thymosin beta-4 accelerated re-epithelialization and reduced inflammation [2]. In murine myocardial infarction models, systemic thymosin beta-4 reduced infarct size and improved functional recovery, with effects attributed to epicardial progenitor cell activation [4].

Pharmacokinetic data specific to TB-500 is limited. The parent thymosin beta-4 protein, administered intravenously in human phase 1 dry-eye and dermal-ulcer trials, displayed a half-life estimated at approximately two hours with rapid distribution into extravascular compartments [5]. TB-500, the seven-residue fragment, would be expected to have a shorter plasma half-life given its smaller size, though formal pharmacokinetic characterization has not been published. The weekly or biweekly dosing intervals common in community protocols are not derived from formal half-life measurements; they reflect, rather, a pragmatic schedule designed to maintain steady tissue exposure given the peptide's hypothesized long biological effect window through actin-binding and progenitor-cell recruitment.

Confusion between TB-500 and thymosin beta-4 is pervasive in commercial descriptions. Many vendors label the full 43-amino-acid protein as "TB-500," while others sell the seven-residue fragment under the same name. The pharmacology and dosing economics of the two are not interchangeable, and readers should verify the sequence by reviewing a vendor's certificate of analysis. Mass-spectrometry data published by independent testing laboratories has shown that some products labeled TB-500 in the research-chemical market actually contain the full thymosin beta-4 protein, while others contain the fragment plus an N-terminal acetylation or additional spacer residues intended to improve solubility. These are meaningfully different molecules with different per-dose mass requirements.

TB-500 Dose Ranges in the Peer-Reviewed Literature

In short: the community protocol is a loading phase of 2–2.5 mg once or twice weekly for 4–6 weeks, followed by maintenance dosing every 2–4 weeks — structurally very different from daily-microgram peptides like BPC-157.

The clearest signature of TB-500 community protocols is the loading-maintenance structure. Unlike BPC-157, which is typically dosed daily at low microgram quantities, TB-500 is dosed in the low-milligram range at weekly intervals, reflecting both its proposed long biological effect window and the substantially higher gross quantities required for reported efficacy. Cost per cycle is correspondingly higher than most peptides in its category.

Allometric scaling from the murine myocardial infarction dose of approximately 150 micrograms per mouse, applied to a seventy-kilogram adult, would project a weekly-equivalent dose in the low-milligram range, which is broadly consistent with community protocols despite the absence of formal human dose-finding. This loose alignment should not be read as validation; body-surface-area conversion is a heuristic, not a dose-equivalence proof, and the research-chemical versions of TB-500 differ in sequence composition from the full Tβ4 protein used in the cited preclinical work.

TB-500 Reconstitution: Math and Worked Examples

In short: because TB-500 is dosed in milligrams rather than micrograms, injection volumes are larger — often close to 1 mL, sometimes split across two sites.

TB-500 is typically supplied as 2 mg, 5 mg, or 10 mg lyophilized vials, with 5 mg being the most common research-market size.

Concentration formula: Concentration (mg/mL) = Vial mass (mg) ÷ Diluent volume (mL)

Worked example — 5 mg vial:

• Vial: 5 mg TB-500
• BAC water added: 2 mL
• Resulting concentration: 2.5 mg/mL (2,500 µg/mL)
• For a 2.5 mg dose: 2.5 mg ÷ 2.5 mg/mL = 1.0 mL = 100 units on a U-100 insulin syringe (which is a full 1 mL syringe)
• For a 2.0 mg dose: 2.0 mg ÷ 2.5 mg/mL = 0.8 mL = 80 units

Worked example — 10 mg vial:

• Vial: 10 mg TB-500
• BAC water added: 2 mL
• Resulting concentration: 5 mg/mL (5,000 µg/mL)
• For a 2.5 mg dose: 2.5 mg ÷ 5 mg/mL = 0.5 mL = 50 units on a U-100 syringe
• For a 2.0 mg dose: 2.0 mg ÷ 5 mg/mL = 0.4 mL = 40 units

Worked example — 2 mg vial:

• Vial: 2 mg TB-500
• BAC water added: 1 mL
• Resulting concentration: 2 mg/mL
• For a 2.0 mg dose: 2.0 mg ÷ 2 mg/mL = 1.0 mL = 100 units (entire vial)

Larger dose volumes are typical of TB-500 relative to most research peptides. When the injection volume approaches or exceeds one milliliter, many protocols split the dose across two separate subcutaneous sites to reduce local tissue distension and discomfort.

How TB-500 Is Administered

In short: subcutaneous is the dominant route; the high injection volumes often warrant a full 1 mL insulin syringe and site rotation across abdomen, thigh, and gluteal regions.

Subcutaneous injection is the predominant route in community and veterinary TB-500 protocols. Abdominal subcutaneous tissue, lateral thigh, and gluteal regions are most commonly used. Site rotation across these regions is standard to reduce cumulative local irritation, particularly given the higher injection volumes characteristic of TB-500 relative to other peptides.

Unlike BPC-157 protocols that often emphasize injection near the injured site, TB-500 is typically described as dosed systemically, with reported effects attributed to the peptide's distribution to injured tissue via recruited progenitor cells and upregulated chemokine gradients [4]. Near-site injection is nonetheless used in some musculoskeletal protocols; no head-to-head comparison has been published.

Needle selection mirrors BPC-157 practice: 29- to 31-gauge insulin syringes of 5/16-inch or 1/2-inch length for subcutaneous delivery. Larger dose volumes may warrant the use of a 1 mL insulin syringe rather than a smaller 0.3 mL or 0.5 mL unit.

Intramuscular injection is described in some veterinary protocols, particularly for equine musculoskeletal use, and occasionally in human community reports. Ophthalmic and topical administration have been studied for the full thymosin beta-4 protein but not meaningfully for the TB-500 fragment [5].

Timing relative to activity or injury has not been formally studied. Some community protocols time the first loading dose to coincide with acute injury, while others initiate TB-500 during the subacute or recovery phase; no controlled data supports either choice.

Storage handling for reconstituted TB-500 mirrors standard peptide practice: refrigeration at 2 to 8 degrees Celsius, avoidance of freeze-thaw cycles after reconstitution, and observed shelf life of approximately 30 days in bacteriostatic water before a measurable decline in HPLC-visible integrity. These conventions are drawn from research-peptide handling norms rather than a TB-500-specific stability publication.

TB-500 Cycle Structure and Protocol Duration

In short: the two-phase loading/maintenance structure is a design hypothesis, not an evidence-based protocol — neither phase has been validated in humans for the fragment.

The defining feature of TB-500 dosing is the two-phase loading and maintenance structure. Loading phase protocols described in the research-chemical community typically involve 2 to 2.5 milligrams subcutaneously once or twice per week for four to six weeks, delivering a cumulative loading dose of approximately 8 to 30 milligrams [3]. Maintenance phase protocols then drop to 2 to 2.5 milligrams every two to four weeks, extended for variable durations depending on the indication.

This structure appears grounded in two hypotheses: first, that thymosin beta-4 peptides exert prolonged biological effects via actin binding and progenitor cell recruitment rather than short-lived receptor occupancy, and second, that tissue saturation during the loading phase is a prerequisite for sustained benefit during maintenance. Neither hypothesis has been formally tested in humans for the TB-500 fragment.

Washout periods between full loading-plus-maintenance courses are inconsistently described. Some protocols recommend a four- to eight-week drug-free interval; others continue maintenance indefinitely. No tolerance, tachyphylaxis, or antibody-formation data has been reported in humans.

TB-500 is prohibited under the WADA code for competitive athletes, both in- and out-of-competition.

TB-500 Side Effects and Safety Profile

In short: no controlled human safety data exists for the fragment. Community reports are mostly mild reactions and occasional "flu-like" lethargy after loading doses; the angiogenic mechanism means cancer history is the key contraindication.

Formal human clinical trial data specific to the TB-500 fragment is effectively absent. Phase 1 and phase 2 trials of the full thymosin beta-4 protein in dry-eye, pressure-ulcer, and epidermolysis bullosa populations have reported generally favorable tolerability, with the most common adverse events being mild application-site reactions for topical formulations and transient infusion-related events for intravenous delivery [5]. These data cannot be directly extrapolated to subcutaneous TB-500 fragment use.

Anecdotal and clinician-reported adverse events from community TB-500 use include transient lethargy or malaise following a loading dose (sometimes referred to as a "flu-like" reaction, and hypothesized to reflect inflammatory mediator release), injection-site discomfort related to higher injection volumes, and occasional headache. Cardiovascular effects are infrequently reported. Long-term safety data is not available.

Contraindications commonly cited in clinician commentary include active or prior malignancy, given thymosin beta-4's documented role in tumor angiogenesis and cancer cell migration in preclinical models, and pregnancy or lactation given absent reproductive data. Theoretical drug interactions have not been formally characterized, though concurrent use with other angiogenesis modulators, anti-cancer agents, and anticoagulants has been flagged in review literature as warranting mechanistic caution given thymosin beta-4's documented vascular activity in preclinical cardiac repair models [4,7]. No formal clinical interaction studies have been conducted for the TB-500 fragment.

TB-500 Vendor Ratings: Who Publishes Lab Data at ≥99% Purity?

Which TB-500 vendors publish lab data at or above 99% purity?

TriedRx aggregates publicly available third-party HPLC and mass-spectrometry reports, transparency disclosures, regulatory actions, and reputation data — then grades vendors on a transparent rubric. Because TB-500 is frequently confused with the full thymosin beta-4 protein in vendor marketing, our rankings specifically flag whether published mass-spec data confirms the molecule matches the labeled sequence. We don't run our own chromatography, accept vendor payments, or run affiliate links on research content.

See all vendors tested for TB-500 → /brands?peptide=tb-500

Related: TB-500 Research Profile and Vendor Rankings

In short: the next pages to read are the Tβ4 profile, the TB-500 profile, and the BPC-157 dosing page for the commonly stacked protocol.

For a full research background on thymosin beta-4 biology, the distinction between TB-500 and the full Tβ4 protein, the preclinical evidence base across cardiac, dermal, corneal, and musculoskeletal indications, and aggregated third-party vendor testing results, see the TriedRx TB-500 peptide profile and the related thymosin beta-4 peptide profile. Readers investigating the commonly stacked BPC-157 protocol should also consult the BPC-157 dosing protocol.

References

1. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. PMID: 16099219.
2. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PMID: 10469335.
3. Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. PMID: 20536465.
4. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID: 15470419.
5. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151. PMID: 20179146.
6. Goldstein AL, Kleinman HK. Advances in the basic and clinical applications of thymosin beta 4. Expert Opin Biol Ther. 2015;15 Suppl 1:S139-S145. PMID: 26098190.
7. Kleinman HK, Sosne G. Thymosin β4 promotes dermal healing. Vitam Horm. 2016;102:251-275. PMID: 27450738.
8. Philp D, Kleinman HK. Animal studies with thymosin beta4, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2010;1194:81-86. PMID: 20536452.